Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments

被引：28

作者：

Laurenti, Luca ^{[1
]}

Innocenti, Idanna ^{[1
]}

Autore, Francesco ^{[1
]}

Vannata, Barbara ^{[2
]}

Efremov, Dimitar G. ^{[3
]}

Ciolli, Stefania ^{[4
]}

Del Poeta, Giovanni ^{[5
]}

Mauro, Francesca Romana ^{[6
]}

Cortelezzi, Agostino ^{[7
]}

Borza, Paola Anticoli ^{[8
]}

Ghio, Francesco ^{[9
]}

Mondello, Patrizia ^{[10
]}

Murru, Roberta ^{[11
]}

Gozzetti, Alessandro ^{[12
]}

Cariccio, Maria Rosa Lanza ^{[13
]}

Piccirillo, Nicola ^{[1
]}

Boncompagni, Riccardo ^{[4
]}

Cantonetti, Maria ^{[5
]}

Del Principe, Maria Ilaria ^{[5
]}

Reda, Gianluigi ^{[7
]}

Bongarzoni, Velia ^{[8
]}

Cervetti, Giulia ^{[9
]}

Pitini, Vincenzo ^{[10
]}

Foa, Robin ^{[6
]}

Sica, Simona ^{[1
]}

D'Arena, Giovanni ^{[14
]}

机构：

[1] Univ Cattolica Sacro Cuore, A Gemelli Policlin, I-00168 Rome, Italy

[2] G Panico Hosp, Haematol Unit, Lecce, Italy

[3] Int Ctr Genet Engn & Biotechnol, Monterotondo, Italy

[4] Careggi Hosp, Florence, Italy

[5] Univ Roma Tor Vergata, Rome, Italy

[6] Univ Roma La Sapienza, Umberto Policlin I, Rome, Italy

[7] Univ Milan, IRCCS Ca Granda, I-20122 Milan, Italy

[8] San Giovanni Addolorata Hosp, Rome, Italy

[9] Santa Chiara Hosp, Pisa, Italy

[10] Univ Messina, Messina, Italy

[11] A Businco Hosp, Cagliari, Italy

[12] Le Scotte Policlin, Siena, Italy

[13] Paolo Giaccone Policlin, Palermo, Italy

[14] IRCCS Ctro Riferimento Oncol Basilicata, Rionero In Vulture, Italy

来源：

LEUKEMIA RESEARCH | 2015年 / 39卷 / 10期

关键词：

CLL; Bendamustine; Rituximab; Elderly patients; First-line treatment; 1ST-LINE TREATMENT; CYCLOPHOSPHAMIDE; CHLORAMBUCIL; FLUDARABINE; TRIAL;

D O I：

10.1016/j.leukres.2015.07.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The front-line therapy for CLL young and fit patients is chemo-immunotherapy with fludarabine-cyclophosphamide-rituximab (FCR). FCR regimen results in a significant myelosuppression and high rates of early and late infections especially in elderly patients. German CLL study group compared FCR vs. bendamustine-rituximab (BR) in fit untreated patients. The response rates with BR or FCR were comparable, BR could be an alternative 1st-line treatment for elderly patients. Here we report retrospective data of 70 elderly (>= 65 years) CLL patients from 12 Italian centers treated with BR as front-line therapy. The primary end points were overall response rate (complete remission/partial remission) and safety. Forty-seven males and 23 females, with a median age of 72 years, were included in the study. Eight patients were unfit for CIRS. The OR rate was 88.6% (31.4% CR and 57.2% PR). Progression free survival, treatment free survival and overall survival rates at 2-years were 79%, 90.3% and 89.6%, respectively. Only del17 was independent unfavorable parameter on the response rate and PFS. Our results indicate that BR front-line at standard dose provides a high response rate with a good safety profile, even if more than 50% of patients experienced a bendamustine dose reduction until 70 mg/m(2). (C) 2015 Elsevier Ltd. All rights reserved.

引用

页码：1066 / 1070

页数：5

共 21 条

[1] Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial [J].

Catovsky, D. ;

Richards, S. ;

Matutes, E. ;

Oscier, D. ;

Dyer, M. J. S. ;

FBezares, R. ;

Pettitt, A. R. ;

Hamblin, T. ;

Milligan, D. W. ;

Child, J. A. ;

Hamilton, M. S. ;

Dearden, C. E. ;

Smith, A. G. ;

Bosanquet, A. G. ;

Davis, Z. ;

Brito-Babapulle, V. ;

Else, M. ;

Wade, R. ;

Hillmen, P. .

LANCET, 2007, 370 (9583) :230-239

[2] Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group [J].

Cueno, Antonio ;

Marchetti, Monia ;

Barosi, Giovanni ;

Billio, Atto ;

Brugiatelli, Maura ;

Ciolli, Stefania ;

Laurenti, Luca ;

Mauro, Francesca Romana ;

Molica, Stefano ;

Montillo, Marco ;

Zinzani, Pierluigi ;

Tura, Sante .

LEUKEMIA RESEARCH, 2014, 38 (11) :1269-1277

[3] Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial [J].

Dreger, Peter ;

Doehner, Hartmut ;

Ritgen, Matthias ;

Boettcher, Sebastian ;

Busch, Raymonde ;

Dietrich, Sascha ;

Bunjes, Donald ;

Cohen, Sandra ;

Schubert, Joerg ;

Hegenbart, Ute ;

Beelen, Dietrich ;

Zeis, Matthias ;

Stadler, Michael ;

Hasenkamp, Justin ;

Uharek, Lutz ;

Scheid, Christof ;

Humpe, Andreas ;

Zenz, Thorsten ;

Winkler, Dirk ;

Hallek, Michael ;

Kneba, Michael ;

Schmitz, Norbert ;

Stilgenbauer, Stephan .

BLOOD, 2010, 116 (14) :2438-2447

[4] Chronic lymphocytic leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Eichhorst, B. ;

Dreyling, M. ;

Robak, T. ;

Montserrat, E. ;

Hallek, M. .

ANNALS OF ONCOLOGY, 2011, 22 :vi50-vi54

[5] Chemoimmunotherapy With Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Bendamustine and Rituximab (BR) In Previously Untreated and Physically Fit Patients (pts) With Advanced Chronic Lymphocytic Leukemia (CLL): Results Of a Planned Interim Trial, International, Randomized Study Of The German CLL Study Group (GCLLSG) [J].

Eichhorst, Barbara ;

Fink, Anna-Maria ;

Busch, Raymonde ;

Lange, Elisabeth ;

Koeppler, Hubert ;

Kiehl, Michael ;

Soekler, Martin ;

Schlag, Rudolf ;

Vehling-Kaiser, Ursula ;

Koechling, Georg ;

Ploeger, Christoph ;

Gregor, Michael ;

Plesner, Torben ;

Trneny, Marek ;

Fischer, Kirsten ;

Doehner, Hartmut ;

Kneba, Michael ;

Wendtner, Clemens ;

Klapper, Wolfram ;

Kreuzer, Karl-Anton ;

Stilgenbauer, Stephan ;

Boettcher, Sebastian ;

Hallek, Michael .

BLOOD, 2013, 122 (21)

[6] Bendamustine in Combination With Rituximab for Previously Untreated Patients With Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group [J].

Fischer, Kirsten ;

Cramer, Paula ;

Busch, Raymonde ;

Boettcher, Sebastian ;

Bahlo, Jasmin ;

Schubert, Joeerg ;

Pflueger, Karl H. ;

Schott, Silke ;

Goede, Valentin ;

Isfort, Susanne ;

von Tresckow, Julia ;

Fink, Anna-Maria ;

Buehler, Andreas ;

Winkler, Dirk ;

Kreuzer, Karl-Anton ;

Staib, Peter ;

Ritgen, Matthias ;

Kneba, Michael ;

Doehner, Hartmut ;

Eichhorst, Barbara F. ;

Hallek, Michael ;

Stilgenbauer, Stephan ;

Wendtner, Clemens-Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (26) :3209-3216

[7] Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients [J].

Foa, Robin ;

Del Giudice, Ilaria ;

Cuneo, Antonio ;

Del Poeta, Giovanni ;

Ciolli, Stefania ;

Di Raimondo, Francesco ;

Lauria, Francesco ;

Cencini, Emanuele ;

Rigolin, Gian Matteo ;

Cortelezzi, Agostino ;

Nobile, Francesco ;

Callea, Vincenzo ;

Brugiatelli, Maura ;

Massaia, Massimo ;

Molica, Stefano ;

Trentin, Livio ;

Rizzi, Rita ;

Specchia, Giorgina ;

Di Serio, Francesca ;

Orsucci, Lorella ;

Ambrosetti, Achille ;

Montillo, Marco ;

Zinzani, Pier Luigi ;

Ferrara, Felicetto ;

Morabito, Fortunato ;

Mura, Maria Angela ;

Soriani, Silvia ;

Peragine, Nadia ;

Tavolaro, Simona ;

Bonina, Silvia ;

Marinelli, Marilisa ;

De Propris, Maria Stefania ;

Della Starza, Irene ;

Piciocchi, Alfonso ;

Alietti, Alessandra ;

Runggaldier, Eva Josephine ;

Gamba, Enrica ;

Mauro, Francesca Romana ;

Chiaretti, Sabina ;

Guarini, Anna .

AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (05) :480-486

[8] Danish CLL2-Study revisited: FISH on a cohort with a 20-yr follow-up confirms the validity of the hierarchical model of genomic aberrations in chronic lymphocytic leukaemia [J].

Geisler, Christian ;

Jurlander, Jesper ;

Bullinger, Lars ;

Sander, Sandrine ;

Brown, Peter ;

Benner, Axel ;

Philip, Preben ;

Doehner, Hartmut ;

Stilgenbauer, Stephan .

EUROPEAN JOURNAL OF HAEMATOLOGY, 2009, 83 (02) :156-158

[9] Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial [J].

Hallek, M. ;

Fischer, K. ;

Fingerle-Rowson, G. ;

Fink, A. M. ;

Busch, R. ;

Mayer, J. ;

Hensel, M. ;

Hopfinger, G. ;

Hess, G. ;

von Gruenhagen, U. ;

Bergmann, M. ;

Catalano, J. ;

Zinzani, P. L. ;

Caligaris-Cappio, F. ;

Seymour, J. F. ;

Berrebi, A. ;

Jaeger, U. ;

Cazin, B. ;

Trneny, M. ;

Westermann, A. ;

Wendtner, C. M. ;

Eichhorst, B. F. ;

Staib, P. ;

Buehler, A. ;

Winkler, D. ;

Zenz, T. ;

Boettcher, S. ;

Ritgen, M. ;

Mendila, M. ;

Kneba, M. ;

Doehner, H. ;

Stilgenbauer, S. .

LANCET, 2010, 376 (9747) :1164-1174

[10] Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines [J].

Hallek, Michael ;

Cheson, Bruce D. ;

Catovsky, Daniel ;

Caligaris-Cappio, Federico ;

Dighiero, Guillaume ;

Doehner, Hartmut ;

Hillmen, Peter ;

Keating, Michael J. ;

Montserrat, Emili ;

Rai, Kanti R. ;

Kipps, Thomas J. .

BLOOD, 2008, 111 (12) :5446-5456

← 1 2 3 →